12:00 AM
May 17, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CD40 Ligand: Phase I data; Phase II

Data from 27 patients showed that the compound was safe and an optimum dose was obtained.


Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >